Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003031 · ClinicalTrials.gov registry record · Phase 3
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
A Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Completed
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
NCT00003031 is a Phase 3 study that has completed, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 212 participants.
The verdict
NCT00003031, a Phase 3 study, has completed, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
Study Summary
RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective treatment for aspergillosis. It is not yet known whether voriconazole is more effective than amphotericin B in treating patients with aspergillosis. PURPOSE: Randomized phase III trial to compare the effectiveness of voriconazole with amphotericin B in treating patients with aspergillosis.
Interventions
- DRUG voriconazole
- DRUG amphotericin B deoxycholate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 1997-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003031
The ClinicalTrials.gov registry entry for NCT00003031 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which voriconazole is the first listed.
NCT00003031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003031 about?
NCT00003031 is a clinical study titled "Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis". RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective treatment for aspergillosis. It is not yet known whether voriconazole is more effective than amphotericin B in treating patients with aspergillosis. PURPOSE: Randomized phase III trial to compare the effectiveness...
What is the current status of trial NCT00003031?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 1997-06.
What interventions are being tested in trial NCT00003031?
The interventions under investigation include: voriconazole (DRUG), amphotericin B deoxycholate (DRUG).
Who is sponsoring clinical trial NCT00003031?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.